Boston Scientific (NYSE: BSX) reported third-quarter 2026 net sales of $5.138 billion, up 1.5% from $5.065 billion a year earlier. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, compared with $755 million, or $0.51 per share, in the prior-year quarter.
The company updated its full-year outlook for approximately 4.25% reported net sales growth and projected fourth-quarter reported and organic net sales declines of 1.0% to 3.0%.
- Third-quarter GAAP diluted EPS was $0.40, versus $0.51 a year earlier.
- MedSurg sales rose 0.6%, while Cardiovascular sales increased 1.9% on a reported basis.
- U.S. sales rose 0.5%; EMEA sales increased 4.4%; APAC sales declined 0.6%; and LACA sales grew 16.0%.
- Boston Scientific began enrollment in the Elite AF clinical trial and received FDA 510(k) clearances for StoneSmart technologies and an expanded SEISMIQ catheter size offering.
$BSX Insider Trading Activity
$BSX insiders have traded $BSX stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:
- MICHAEL F MAHONEY (Chairman, President & CEO) purchased 186,240 shares for an estimated $9,001,407
- EDWARD J LUDWIG has made 2 purchases buying 8,580 shares for an estimated $430,313 and 0 sales.
- DAVID C HABIGER has made 5 purchases buying 7,732 shares for an estimated $407,921 and 0 sales.
- SUSAN E MORANO purchased 2,040 shares for an estimated $100,407
- CHERYL PEGUS purchased 1,770 shares for an estimated $99,987
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BSX Hedge Fund Activity
We have seen 739 institutional investors add shares of $BSX stock to their portfolio, and 939 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 28,523,550 shares (-38.4%) from their portfolio in Q2 2026, for an estimated $1,217,385,114
- JPMORGAN CHASE & CO added 23,907,838 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,020,386,525
- PRIMECAP MANAGEMENT CO/CA/ added 17,991,140 shares (+55.3%) to their portfolio in Q2 2026, for an estimated $767,861,855
- D. E. SHAW & CO., INC. added 14,208,205 shares (+126.3%) to their portfolio in Q2 2026, for an estimated $606,406,189
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 13,862,619 shares (+126.1%) to their portfolio in Q2 2026, for an estimated $591,656,578
- TWO SIGMA INVESTMENTS, LP added 9,947,792 shares (+105.7%) to their portfolio in Q2 2026, for an estimated $424,571,762
- BANK OF AMERICA CORP /DE/ removed 9,728,863 shares (-42.8%) from their portfolio in Q2 2026, for an estimated $415,227,872
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BSX Congressional Stock Trading
Members of Congress have traded $BSX stock 13 times in the past 6 months. Of those trades, 5 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:
- REPRESENTATIVE KEVIN HERN has traded it 6 times. They made 0 purchases and 6 sales worth up to $295,000 on 09/09, 09/04, 09/03, 08/31.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 6 times. They made 5 purchases worth up to $75,000 on 08/18, 06/05, 05/29, 05/19, 05/11 and 1 sale worth up to $15,000 on 06/05.
- SENATOR JOHN BOOZMAN sold up to $15,000 on 06/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
